The lncRNA CCAT2 Rs6983267 G Variant Contributes to Increased Sepsis Susceptibility in a Southern Chinese Population

Infect Drug Resist. 2021 Aug 4:14:2969-2976. doi: 10.2147/IDR.S311717. eCollection 2021.

Abstract

Purpose: Accumulating evidence demonstrates that genetic susceptibility genes can be used as biomarkers to assess sepsis susceptibility, and genetic variation is associated with susceptibility and clinical outcomes in patients with sepsis and inflammatory disease. Although studies have shown that the lncRNA CCAT2 is involved in inflammatory diseases, it remains unclear whether CCAT2 gene polymorphisms are associated with susceptibility to inflammatory diseases, such as sepsis, in children.

Methods: We genotyped the rs6983267 CCAT2 polymorphism in 474 cases (pediatric sepsis) and 678 controls using TaqMan methods, and odds ratios (ORs) and 95% confidence intervals (CIs) were used to evaluate the strength of associations.

Results: Our results indicate that the rs6983267 T > G polymorphism is significantly associated with an increased risk of sepsis in children (TG and TT: adjusted OR = 1.311, 95% CI = 1.016-1.743, GG and TT: adjusted OR = 1.444, 95% CI = 1.025-2.034 dominant model: GG/TG vs TT adjusted OR = 1.362, 95% CI = 1.055-1.756). Furthermore, the risk effect was more pronounced in children younger than 60 months who were male and who had sepsis.

Conclusion: We found that the CCAT2 gene polymorphism rs6983267 T > G may be associated with an increased risk of pediatric sepsis in southern China. A larger multicenter study should be performed to confirm these results.

Keywords: lncRNA CCAT2; polymorphism; sepsis; susceptibility.

Grants and funding

This study was funded by the Guangzhou Science and Technology Program Project, China (grant numbers 201904010486, 202102010197), the Guangdong Natural Science Fund, China (grant numbers 2021A1515011207, 2019A1515012061), and the Guangzhou Institute of Pediatrics/Guangzhou Women and Children’s Medical Center Fund, China (Grant Number: GCP-2019-006, GCP-2019-003).